As an oncogene, overexpression of SOX2 is linked to increased cellular replication rates, aggressive tumor grades and poor patient outcomes in breast carcinoma (BRCA) (41–45), colon adenocarcinoma (COAD) (46–49), glioblastoma (GBM) (50–53), liver hepatocellular carcinoma (LIHC) (54), lung adenocarcinoma (LUAD) (55–57) and lung squamous cell carcinoma (LUSC) (58,59). The gene discussed is SOX2; the disease is breast carcinoma.